C
Cureatr
Group messaging apps for healthcare providers to overcome care-coordination challenges that result in delays and errors
About Cureatr
Cureatr was founded in 2011 by Dr. Joseph Mayer and Alex Khomenko in New York City. The company emerged as a pioneer in healthcare technology, focusing on providing cloud-based medication management solutions. Their platform aimed to enhance care coordination and communication across the healthcare continuum, offering real-time clinical notifications to healthcare providers.
Over the years, Cureatr attracted significant attention from investors, raising a total of $41.4 million over multiple funding rounds. This financial backing allowed the company to expand its offerings and solidify its position in the healthcare tech industry.
In a strategic move to broaden its capabilities, Cureatr acquired SinfoniaRx in March 2023. This acquisition was a testament to Cureatr's commitment to enhancing its medication management solutions and expanding its technological footprint.
The journey took a pivotal turn in June 2024 when Cureatr itself was acquired by AssureCare, a leading healthcare technology company. This acquisition marked a new chapter for Cureatr, integrating its innovative solutions into AssureCare's broader portfolio, thereby amplifying its impact on medication management and healthcare coordination.
Cureatr's story is one of innovation and strategic growth, navigating the complex landscape of healthcare technology to deliver impactful solutions that improve patient care and provider efficiency.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2011
- Headquarters
- New York City, United States
- Employees
- 29
- Open positions
- None listed
- Dealroom signal
- 71.5/100
- Industry
- Health
- Sub-industry
- Health Platform
- Sector
- Health Tech & Medtech, Medication Adherence, Patient Care, Tech for Hospitals and Clinics, Hard Tech
- Business model
- SaaS
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Aug 2023 | $7.5M | $30M | Undisclosed | — |
| DEBTDebt | Mar 2023 | $9M | — | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Cureatr is 1.2K monthly website visits, down 60% over the last three months. Cureatr's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
Cardinal Partners
Activate Venture Partners
JMI Equity
Partnership Fund for New York City- CBCarl Byers
Deerfield
Windham Venture Partners
Series B and later3 investors entered at this stage
New York Ventures- CCCerner Capital
Sarah Imbach
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cureatr on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cureatr’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.